dBET57 is a potent and selective BET (bromodomain and extra-terminal) protein inhibitor used primarily in biomedical research. It functions by disrupting the interaction between BET proteins and acetylated histones, leading to the suppression of oncogenic gene expression. This compound is widely applied in cancer research, particularly in studies involving hematological malignancies such as leukemia and multiple myeloma, where it induces cell cycle arrest and apoptosis in tumor cells. It is also utilized as a chemical probe to study the role of BET proteins in transcriptional regulation and epigenetic signaling pathways. Due to its rapid and reversible mechanism, dBET57 is valuable in target validation experiments and in the development of degrader-based therapeutics, including PROTACs (proteolysis-targeting chimeras). Its high specificity and cellular permeability make it suitable for in vitro and in vivo studies aimed at understanding epigenetic drivers of disease.